Trial Outcomes & Findings for Pharmacogenetic Testing Among Home Health Patients (NCT NCT02378220)
NCT ID: NCT02378220
Last Updated: 2019-09-20
Results Overview
The primary outcomes included the number of re-hospitalizations at 30 and 60 days.
COMPLETED
NA
110 participants
30 days, 60 days post discharge
2019-09-20
Participant Flow
Study was conducted at a hospital-based HHA in Searcy, Arkansas. The study population was derived from patient referrals to home health upon hospital discharge. Of 655 patients assessed for eligibility, 412 did not meet the inclusion criteria and 133 patients declined to participate.
Exclusion criteria were the same for tested and untested groups and included patients previously tested for CYP 450, history of organ transplant, current malabsorption, treatment of invasive solid tumors or hematologic malignancies in the last year, end stage renal disease or current dialysis.
Participant milestones
| Measure |
Controls ("Not Tested")
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Overall Study
STARTED
|
53
|
57
|
|
Overall Study
COMPLETED
|
47
|
56
|
|
Overall Study
NOT COMPLETED
|
6
|
1
|
Reasons for withdrawal
| Measure |
Controls ("Not Tested")
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Overall Study
Death
|
6
|
1
|
Baseline Characteristics
Pharmacogenetic Testing Among Home Health Patients
Baseline characteristics by cohort
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
Total
n=110 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
14 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
20 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
39 Participants
n=99 Participants
|
51 Participants
n=107 Participants
|
90 Participants
n=206 Participants
|
|
Age, Continuous
|
74.6 years
STANDARD_DEVIATION 11.9 • n=99 Participants
|
76.5 years
STANDARD_DEVIATION 9.4 • n=107 Participants
|
75.6 years
STANDARD_DEVIATION 10.7 • n=206 Participants
|
|
Sex: Female, Male
Female
|
36 Participants
n=99 Participants
|
32 Participants
n=107 Participants
|
68 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
17 Participants
n=99 Participants
|
25 Participants
n=107 Participants
|
42 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
52 Participants
n=99 Participants
|
57 Participants
n=107 Participants
|
109 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
53 participants
n=99 Participants
|
57 participants
n=107 Participants
|
110 participants
n=206 Participants
|
|
OASIS Metrics
OVERALL OASIS SCORE
|
1.63 Scores on a scale
n=99 Participants
|
1.64 Scores on a scale
n=107 Participants
|
1.63 Scores on a scale
n=206 Participants
|
|
OASIS Metrics
AVERAGE PHARMACOGENETIC RISK
|
34.3 Scores on a scale
n=99 Participants
|
33.2 Scores on a scale
n=107 Participants
|
33.75 Scores on a scale
n=206 Participants
|
PRIMARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: Primary outcomes included the number of re-hospitalizations between the tested group and the untested group at 30 and 60 days post-discharge.
The primary outcomes included the number of re-hospitalizations at 30 and 60 days.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Number of Re-hospitalizations at 30 and 60 Days
Re-hospitalizations at 30 Days
|
0.38 Re-hospitalizations
Interval 0.0 to 2.0
|
0.25 Re-hospitalizations
Interval 0.0 to 3.0
|
|
Number of Re-hospitalizations at 30 and 60 Days
Re-hospitalizations at 60 Days
|
0.7 Re-hospitalizations
Interval 0.0 to 3.0
|
0.33 Re-hospitalizations
Interval 0.0 to 3.0
|
PRIMARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The primary outcomes assessed the number of emergency department visits between the tested group and the untested group at 30 and 60 days post-discharge.
Assessed the number of Emergency Department visits at 30 and 60 days post discharge with pharmacogenetic testing and YouScript® Personalized Prescribing system.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
The Primary Outcomes Included the Number of Emergency Department Visits at 30 and 60 Days.
ED Visits at 30 Days
|
0.40 ED visits
Interval 0.0 to 2.0
|
0.25 ED visits
Interval 0.0 to 2.0
|
|
The Primary Outcomes Included the Number of Emergency Department Visits at 30 and 60 Days.
ED Visits at 60 Days
|
0.66 ED visits
Interval 0.0 to 4.0
|
0.39 ED visits
Interval 0.0 to 2.0
|
SECONDARY outcome
Timeframe: 30 days, 60 daysPopulation: We compared the exploratory time-to-event outcomes between the tested and untested groups at 30 days and 60 days.
To assess time to first re-hospitalization, we compared the exploratory time-to-event outcomes between the tested and untested groups at 30 days and 60 days. These outcomes were measured using cumulative percentage events at 30 and 60 days, referring to the percentage of subjects re-hospitalized before or at 30 and 60 days.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Time to 1st Re-hospitalization
Cumulative Percentage Events at 30 Days
|
29 Percentage of participants
|
19 Percentage of participants
|
|
Time to 1st Re-hospitalization
Cumulative Percentage Events at 60 Days
|
43 Percentage of participants
|
28 Percentage of participants
|
SECONDARY outcome
Timeframe: 30 days, 60 daysPopulation: Compared the exploratory time-to-event outcomes between the tested and untested groups at 30 days and 60 days.
To assess time to first emergency department visit, we compared the exploratory time-to-event outcomes (time to 1st ED visit) between the tested and untested groups at 30 days and 60 days. These outcomes were measured using cumulative percentage events at 30 and 60 days, referring to the percentage of subjects who visited the emergency department before or at 30 and 60 days.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Time to 1st Emergency Department Visit
Cumulative Percentage Events at 30 Days
|
30 Percentage of participants
|
23 Percentage of participants
|
|
Time to 1st Emergency Department Visit
Cumulative Percentage Events at 60 Days
|
49 Percentage of participants
|
32 Percentage of participants
|
SECONDARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The secondary outcomes assessed the overall status according to OASIS M1034 of the tested group and the untested group at 30 and 60 days post-discharge.
We assessed the impact of genetic testing on overall status according to OASIS M1034 at 30 and 60 days post discharge. OASIS measures various data items to assess home health care quality and performance. OASIS M1034, one data point in the OASIS system, measures overall patient status on a scale of 0 to 3, with a lower score indicating better overall status.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Overall Status as Measured by Outcome and Assessment Information Set (OASIS) Scale
OASIS M1034 at 30 Days
|
1.00 Scores on a scale
Interval 0.0 to 2.0
|
1.11 Scores on a scale
Interval 0.0 to 3.0
|
|
Overall Status as Measured by Outcome and Assessment Information Set (OASIS) Scale
OASIS M1034 at 60 Days
|
0.76 Scores on a scale
Interval 0.0 to 3.0
|
0.71 Scores on a scale
Interval 0.0 to 3.0
|
SECONDARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The secondary outcomes assessed frequency of pain according to OASIS M1242 of the tested group and the untested group at 30 and 60 days post-discharge.
We assessed the impact of genetic testing on patient pain frequency according to OASIS M1242 at 30 and 60 days post discharge. OASIS measures various data items to assess home health care quality and performance. OASIS M1242, one data point in the OASIS system, measures patient pain frequency on a scale of 0 to 4, with a lower score indicating less frequent pain.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Pain as Measured by OASIS Scale
OASIS M1242 at 30 Days
|
1.02 Scores on a scale
Interval 0.0 to 4.0
|
1.16 Scores on a scale
Interval 0.0 to 4.0
|
|
Pain as Measured by OASIS Scale
OASIS M1242 at 60 Days
|
1.19 Scores on a scale
Interval 0.0 to 4.0
|
1.49 Scores on a scale
Interval 0.0 to 4.0
|
SECONDARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The secondary outcomes assessed frequency of confusion according to OASIS M1710 of the tested group and the untested group at 30 and 60 days post-discharge.
We assessed the impact of genetic testing on frequency of confusion according to OASIS M1710 at 30 and 60 days post discharge. OASIS measures various data items to assess home health care quality and performance. OASIS M1710, one data point in the OASIS system, measures patient confusion frequency on a scale of 0 to 4, with a lower score indicating less frequent confusion.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Confusion as Measured by OASIS Scale
OASIS M1710 at 30 Days
|
0.49 Scores on a scale
Interval 0.0 to 4.0
|
0.66 Scores on a scale
Interval 0.0 to 3.0
|
|
Confusion as Measured by OASIS Scale
OASIS M1710 at 60 Days
|
0.79 Scores on a scale
Interval 0.0 to 4.0
|
0.61 Scores on a scale
Interval 0.0 to 4.0
|
SECONDARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The secondary outcomes assessed frequency of anxiety according to OASIS M1720 of the tested group and the untested group at 30 and 60 days post-discharge.
We assessed the impact of genetic testing on frequency of anxiety according to OASIS M1720 at 30 and 60 days post discharge. OASIS measures various data items to assess home health care quality and performance. OASIS M1720, one data point in the OASIS system, measures patient confusion frequency on a scale of 0 to 3, with a lower score indicating less frequent confusion.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Anxiety as Measured by OASIS Scale
OASIS M1720 at 30 Days
|
0.51 Scores on a scale
Interval 0.0 to 3.0
|
0.41 Scores on a scale
Interval 0.0 to 2.0
|
|
Anxiety as Measured by OASIS Scale
OASIS M1720 at 60 Days
|
0.67 Scores on a scale
Interval 0.0 to 3.0
|
0.55 Scores on a scale
Interval 0.0 to 2.0
|
SECONDARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The secondary outcomes assessed feelings of depression according to PHQ-2 of the tested group and the untested group at 30 and 60 days post-discharge.
We assessed the impact of genetic testing on frequency of depressive mood according to PHQ-2 at 30 and 60 days post discharge. PHQ-2 evaluates patient depression by assessing two factors: frequency of little interest or pleasure in doing things and frequency of feeling down, depressed, or hopeless. This outcome measure assessed the second factor, frequency of feeling down or depressed. The scale for this factor ranges from 0 to 3, with a lower score represented less frequent depressive feelings.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Depression as Measured by Patient Health Questionnaire (PHQ)-2 Scale
OASIS PHQ-2 at 30 Days
|
0.06 Scores on a scale
Interval 0.0 to 1.0
|
0.16 Scores on a scale
Interval 0.0 to 2.0
|
|
Depression as Measured by Patient Health Questionnaire (PHQ)-2 Scale
OASIS PHQ-2 at 60 Days
|
0.59 Scores on a scale
Interval 0.0 to 3.0
|
0.35 Scores on a scale
Interval 0.0 to 2.0
|
SECONDARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The secondary outcomes assessed frequency of disruptive behavior according to OASIS M1745 of the tested group and the untested group at 30 and 60 days post-discharge.
We assessed the impact of genetic testing on frequency of disruptive behavior according to OASIS M1745 at 30 and 60 days post discharge. OASIS measures various data items to assess home health care quality and performance. OASIS M1745, one data point in the OASIS system, measures frequency of disruptive behavior by patient on a scale of 0 to 5, with a lower score indicating less frequent disruptive behavior.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Disruptive Behavior as Measured by OASIS Scale
OASIS M1745 at 30 Days
|
0.06 Scores on a scale
Interval 0.0 to 1.0
|
0.05 Scores on a scale
Interval 0.0 to 1.0
|
|
Disruptive Behavior as Measured by OASIS Scale
OASIS M1745 at 60 Days
|
0.45 Scores on a scale
Interval 0.0 to 5.0
|
0.14 Scores on a scale
Interval 0.0 to 3.0
|
SECONDARY outcome
Timeframe: 30 days, 60 days post dischargePopulation: The secondary outcomes assessed frequency of ADL and IADL according to OASIS M2110 of the tested group and the untested group at 30 and 60 days post-discharge.
We assessed the impact of genetic testing on the frequency of activities of daily living (ADL) and instrumental activities of daily living (IADL) assistance according to OASIS M2110 at 30 and 60 days post discharge. OASIS measures various data items to assess home health care quality and performance. OASIS M2110, one data point in the OASIS system, measures frequency of receiving ADL/IADL assistance on a scale of 0 to 5, with a lower score indicating less frequent assistance.
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Activities of Daily Living as Measured by OASIS Scale
OASIS M2110 at 30 Days
|
2.72 Scores on a scale
Interval 1.0 to 5.0
|
2.30 Scores on a scale
Interval 1.0 to 5.0
|
|
Activities of Daily Living as Measured by OASIS Scale
OASIS M2110 at 60 Days
|
2.86 Scores on a scale
Interval 1.0 to 5.0
|
2.76 Scores on a scale
Interval 1.0 to 5.0
|
SECONDARY outcome
Timeframe: 60 daysTo assess whether YouScript® testing decreases falls
Outcome measures
| Measure |
Controls ("Not Tested")
n=53 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
n=57 Participants
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Number of Falls as Measured by Tabulation
|
0.09 Falls
Interval 0.0 to 1.0
|
0.11 Falls
Interval 0.0 to 1.0
|
SECONDARY outcome
Timeframe: 60 daysPopulation: This secondary outcome assessed the proportion of YouScript® Personalized Prescribing System recommendations provided for patients in the "tested" group accepted by the study pharmacist and passed to clinicians.
To assess the proportion of YouScript® Personalized Prescribing System recommendations accepted by the study pharmacist and passed on to clinicians.
Outcome measures
| Measure |
Controls ("Not Tested")
n=57 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Number of Pharmacist-accepted of Recommendations as Measured by Tabulation
Number of YouScript® Recommendations Made
|
124 recommendations
|
—
|
|
Number of Pharmacist-accepted of Recommendations as Measured by Tabulation
Number of YouScript® Recommendations Accepted
|
124 recommendations
|
—
|
SECONDARY outcome
Timeframe: 60 daysPopulation: This secondary outcome assessed the proportion of YouScript® Personalized Prescribing System recommendations provided for patients in the "tested" group acted on by clinicians.
To assess the proportion of study pharmacist recommendations acted on by clinicians.
Outcome measures
| Measure |
Controls ("Not Tested")
n=57 Participants
Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
|
Intervention ("Tested")
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers.
Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System
|
|---|---|---|
|
Number of Clinician-accepted of Recommendations as Measured by Tabulation
Number of Recommendations Passed to Clinicians
|
124 recommendations
|
—
|
|
Number of Clinician-accepted of Recommendations as Measured by Tabulation
Number of Recommendations Followed
|
96 recommendations
|
—
|
|
Number of Clinician-accepted of Recommendations as Measured by Tabulation
Number of Recommendations Not Followed
|
6 recommendations
|
—
|
|
Number of Clinician-accepted of Recommendations as Measured by Tabulation
Number of Unknown Status Recommendations
|
22 recommendations
|
—
|
Adverse Events
Controls ("Not Tested")
Intervention ("Tested")
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Lindsay Elliott
Harding University College of Pharmacy / Unity Health - White County Medical Center, Searcy, Arkansas, USA
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place